Management of nonresponsive hepatitis C

References

• Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med.340(16), 1228–1233 (1999).
   PubMed Web of Science ®Google Scholar
• Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med.345(1), 41–52 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• NIH. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 – June 10–12, 2002. Hepatology36(5 Suppl 1), S3–S20 (2002).
   PubMed Web of Science ®Google Scholar
• Desmond CP, Roberts SK, Dudley F et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J. Viral Hepat.13(5), 311–315 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuda N, Yuki N, Mochizuki K et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol.74(3), 406–413 (2004).
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Saracco G, Boyer N et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut53(10), 1504–1508 (2004).
   PubMed Web of Science ®Google Scholar
• Heathcote J. Retreatment of chronic hepatitis C: who and how? Liver Int.29(Suppl. 1), 49–56 (2009).
   PubMed Web of Science ®Google Scholar
• Barcena R, Moreno A, del Campo S et al. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1. Antivir. Ther.12(3), 401–406 (2007).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Hofmann CM, Thompson EB et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology26(3), 780–785 (1997).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D. Development of novel agents for the treatment of chronic hepatitis C infection: summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology46(6), 2014–2020 (2007).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology123(4), 1061–1069 (2002).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology126(4), 1015–1023; discussion 1947 (2004).
   PubMed Web of Science ®Google Scholar
• Foy E, Li K, Wang C et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science300(5622), 1145–1148 (2003).
   PubMed Web of Science ®Google Scholar
• Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature436(7053), 939–945 (2005).
   PubMed Web of Science ®Google Scholar
• Lin W, Choe WH, Hiasa Y et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology128(4), 1034–1041 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science285(5424), 107–110 (1999).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140(5), 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA105(19), 7034–7039 (2008).
   PubMed Web of Science ®Google Scholar
• Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science288(5464), 339–344 (2000).
   PubMed Web of Science ®Google Scholar
• Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev.20(1), 23–38 (2007).
   PubMed Web of Science ®Google Scholar
• Fan X, Mao Q, Zhou D et al. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology50(6), 1765–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol.49(4), 634–651 (2008).
   PubMed Web of Science ®Google Scholar
• Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology47(1), 43–50 (2008).
   PubMed Web of Science ®Google Scholar
• Antonucci G, Longo MA, Angeletti C et al. The effect of age on response to therapy with peginterferon α plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am. J. Gastroenterol.102(7), 1383–1391 (2007).
   PubMed Web of Science ®Google Scholar
• Bakr I, Rekacewicz C, El Hosseiny M et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut55(8), 1183–1187 (2006)
   PubMed Web of Science ®Google Scholar
• Inoue G, Horiike N, Michitaka K, Onji M. Hepatitis C virus clearance is prominent in women in an endemic area. J. Gastroenterol. Hepatol.15(9), 1054–1058 (2000).
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet352(9138), 1426–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology131(2), 470–477 (2006).
   PubMed Web of Science ®Google Scholar
• Gheorghe L, Iacob S, Grigorescu M et al. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C. J. Gastrointestin. Liver Dis.18(1), 51–56 (2009).
   PubMed Web of Science ®Google Scholar
• Sezaki H, Suzuki F, Kawamura Y et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig. Dis. Sci.54(6), 1317–1324 (2009).
   PubMed Web of Science ®Google Scholar
• Hung CH, Lee CM, Lu SN et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int.26(9), 1079–1086 (2006).
   PubMed Web of Science ®Google Scholar
• Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med.350(22), 2265–2271 (2004).
   PubMed Web of Science ®Google Scholar
• Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am. J. Gastroenterol.102(10), 2181–2188 (2007).
   PubMed Web of Science ®Google Scholar
• Tai AW, Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J. Hepatol.50(2), 412–420 (2009).
   PubMed Web of Science ®Google Scholar
• Rosen HR, Weston SJ, Im K et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology46(2), 350–358 (2007).
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature461(7262), 399–401 (2009).
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet.41(10), 1100–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet.41(10), 1105–1109 (2009).
   PubMed Web of Science ®Google Scholar
• O’Brien TR. interferon-α, interferon-λ and hepatitis C. Nat. Genet. (2009) (Epub ahead of print).
   Google Scholar
• Diago M, Castellano G, Garcia-Samaniego J et al. Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut55(3), 374–379 (2006).
   PubMed Web of Science ®Google Scholar
• Butera D, Marukian S, Iwamaye AE et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood106(4), 1175–1182 (2005).
   PubMed Web of Science ®Google Scholar
• Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-γ inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev.8(3), 207–219 (1997).
   PubMedGoogle Scholar
• Lagging M, Romero AI, Westin J et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology44(6), 1617–1625 (2006).
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Kleiner DE, Everhart JE et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology45(1), 80–87 (2007).
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology128(3), 636–641 (2005).
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol.165(5), 1499–1508 (2004).
   PubMed Web of Science ®Google Scholar
• Castera L. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Minerva Gastroenterol. Dietol.52(2), 125–134 (2006).
   PubMedGoogle Scholar
• Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J. Viral Hepat.16(10), 681–688 (2009).
   PubMed Web of Science ®Google Scholar
• Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology38(3), 639–644 (2003).
   PubMed Web of Science ®Google Scholar
• Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology43(6), 1177–1186 (2006).
   PubMed Web of Science ®Google Scholar
• Huang PL. A comprehensive definition for metabolic syndrome. Dis. Model. Mech.2(5–6), 231–237 (2009).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA292(23), 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med.351(5), 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Tural C, Galeras JA, Planas R et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV–HIV-coinfected patients. Antivir. Ther.13(8), 1047–1055 (2008).
   PubMed Web of Science ®Google Scholar
• Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs68(1), 27–42 (2008).
   PubMed Web of Science ®Google Scholar
• Camma C, Di Bona D, Schepis F et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology39(2), 333–342 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshida H, Arakawa Y, Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology123(2), 483–491 (2002).
   PubMed Web of Science ®Google Scholar
• Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology124(1), 97–104 (2003).
   PubMed Web of Science ®Google Scholar
• Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Haussinger D. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver Int.27(7), 954–959 (2007).
   PubMed Web of Science ®Google Scholar
• Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics42(5), 411–415 (2001).
   PubMed Web of Science ®Google Scholar
• Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J. Viral Hepat.11(1), 84–87 (2004).
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dieterich DT, Pockros PJ et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology126(5), 1302–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Wasserman R, Brau N et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am. J. Gastroenterol.98(11), 2491–2499 (2003).
   PubMed Web of Science ®Google Scholar
• Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J. Clin. Gastroenterol.39(1 Suppl.), S9–S13 (2005).
   Web of Science ®Google Scholar
• Lebray P, Nalpas B, Vallet-Pichard A et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir. Ther.10(6), 769–776 (2005).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N. Engl. J. Med.357(22), 2227–2236 (2007).
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-α in patients affected by hepatitis C virus. J. Affect. Dis.72(3), 237–241 (2002).
   PubMed Web of Science ®Google Scholar
• Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-α: recognition and management. CNS Drugs19(2), 105–123 (2005).
   PubMed Web of Science ®Google Scholar
• Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon α: a review. Am. J. Psychiatry157(6), 867–876 (2000).
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Schottker K et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut57(4), 531–536 (2008).
   PubMed Web of Science ®Google Scholar
• Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med.344(13), 961–966 (2001).
   PubMed Web of Science ®Google Scholar
• Larrey D, Salse A, Pageaux GP et al. Effects of systematic nurse-provided therapeutic education on adherence and efficiency of PEG-interferon-α2a (Pegasys®)-ribavirin treatment in chronic hepatitis C (pegobs protocol). J. Hepatol.48(Suppl. 2), S300 (2008).
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology130(4), 1086–1097 (2006).
   PubMed Web of Science ®Google Scholar
• Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology131(2), 451–460 (2006).
   PubMed Web of Science ®Google Scholar
• Jensen DM, Freilich B, Andreone P et al. Pegylated interferon α-2A (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon α-2B (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study. Hepatology46(4), 291A–292A (2007).
   PubMed Web of Science ®Google Scholar
• Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J. Viral Hepat.9(5), 334–339 (2002).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med.359(23), 2429–2441 (2008).
   PubMed Web of Science ®Google Scholar
• Poynard T, Colombo M, Bruix J et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology136(5), 1618–1628.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Gross J, Johnson S, Kwo P, Afdhal N, Flamm S, Therneau T. Double-dose peginterferon alfa-2B with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of RENEW. Hepatology42 (Suppl. 1)(4), 219A–220A (2005).
   Google Scholar
• White C, Wentworth C, Malet P et al. The target trial: final results using 3.0 mu g/kg pegylated interferon alfa 2-b (Peg;Peg-intron®) plus ribavirin (RBV;rebetol®) for chronic hepatitis C patients who were non-responders (NR) and relapsers (R) to previous therapy. Hepatology42(Suppl. 1)(4), 651A (2005).
   Google Scholar
• Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir. Ther.13(4), 607–611 (2008).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin a. Hepatology46(2), 371–379 (2007).
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Diago M, Andrade R et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naive genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial. Hepatology (Suppl. S)(4), 380A (2008).
   Google Scholar
• Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive patients. Hepatology48 (Suppl. S)(4), 383A (2008).
   Web of Science ®Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology130(1), 225–230 (2006).
   PubMed Web of Science ®Google Scholar
• Alric L, Duffaut M, Selves J et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J. Hepatol.35(2), 272–278 (2001).
   PubMed Web of Science ®Google Scholar
• Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann. Intern. Med.129(2), 94–99 (1998).
   PubMed Web of Science ®Google Scholar
• Manabe N, Chevallier M, Chossegros P et al. Interferon-α 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology18(6), 1344–1349 (1993).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Hofmann CM, Contos MJ et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology117(5), 1164–1172 (1999).
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology122(5), 1303–1313 (2002).
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Levine R, Brown R, Freilich B, O’Brien M, Brass C. Colchicine versus PEG-interferon alfa-2b long term therapy: results of the 4 year COPILOT trial. J. Hepatol.48(Suppl. 2), S4 (2008).
   Google Scholar
• Cardenas A, Pritchett S, Brown RS, Levine RA, Curry MP, Afdhal N. The effects of long term PEG-interferon therapy on the development of esophageal varices and variceal bleeding jn patients with hepatitis C and advanced fibrosis: final results from the Copilot trial. Gastroenterology136 (Suppl. 1)(5), A795 (2009).
   Google Scholar
• Shiffman ML. What future for ribavirin? Liver Int.29(Suppl. 1), 68–73 (2009).
   PubMed Web of Science ®Google Scholar
• Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology26(2), 473–477 (1997).
   PubMed Web of Science ®Google Scholar
• Zoulim F, Haem J, Ahmed SS et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J. Viral Hepat.5(3), 193–198 (1998).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Ghany MG, Kleiner DE et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology38(1), 66–74 (2003).
   PubMed Web of Science ®Google Scholar
• Trepo C, Bonaventure C, Calay V, Chevallier M, Merle P, Pradat P. Long-term maintenance ribavirin monotherapy in chronic hepatitis C patients not responding or intolerant to interferon α. J. Clin. Virol.36, S39 (2006).
   Google Scholar
• Omata M, Yoshida H, Toyota J et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut56(12), 1747–1753 (2007).
   PubMed Web of Science ®Google Scholar
• Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin. Gastroenterol. Hepatol.3(10 Suppl. 2), S141–S143 (2005).
   Google Scholar
• Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther.15(5), 689–698 (2001).
   PubMed Web of Science ®Google Scholar
• Bacon BR, Shiffman ML, Mendes F et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology49(6), 1838–1846 (2009).
   PubMed Web of Science ®Google Scholar
• Ghalib R, Levine CD, Friedman DA, Rashdan S, Schwartz A, Weinstein J. Consensus interferon plus ribavirin therapy in patients who are nonresponders or relapsers to prior PEG IFN plus ribavirin. Gastroenterology132 (Suppl. 2)(4), A794 (2007).
   PubMed Web of Science ®Google Scholar
• Kaiser S, Boecher W, Schlaak JF et al. Treatment of PEG-interferon/ribavirin nonresponders with daily dosing of consensus interferon and ribavirin – preliminary results of the German consensus interferon multicenter study. Hepatology46 (Suppl. 1)(4), 817A (2007).
   Google Scholar
• Trepo C, Pradat P. CIFN for re-treatment of PEG-IFN plus RBV nonresponders? Nat. Rev. Gastroenterol. Hepatol.6(10), 570–571 (2009).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Zeuzem S, Lawitz E et al. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment naive patients with chronic hepatitis C genotype 1. Hepatology50(Suppl. S)(4), 333A (2009).
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Jeffers L, Afdhal N et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology45(3), 569–578 (2007).
   PubMed Web of Science ®Google Scholar
• Trepo C, Guest M, Meyrueix R et al. Evaluation of antiviral activity and tolerance of a novel sustained release interferon α-2b (IFN α-2βXL) compared to pegylated interferon α-2b (PEG-IFN α-2b): a Phase 1B trial in HCV patients. J. Hepatol.48 (Suppl. 2), S28 (2008).
   PubMed Web of Science ®Google Scholar
• Schiff E, Poordad E, Jacobson I et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J. Hepatol.48(Suppl. 2), S46 (2008).
   Web of Science ®Google Scholar
• Manns M, Muir A, Adda N et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to PEG-IFN-αlfa-2a/b and ribavirin therapy: SVR results of the PROVE3 study. J. Hepatol.50(Suppl. 1), S379 (2009).
   Google Scholar
• Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int.29(Suppl. 1), 15–18 (2009).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology36(5 Suppl. 1), S47–S56 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Strathdee SA, Vlahov D. Long-term prognosis of hepatitis C virus infection. JAMA284(20), 2592 (2000).
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol.34(5), 730–739 (2001).
   PubMed Web of Science ®Google Scholar
• Bedossa P. Assessment of hepatitis C: non-invasive fibrosis markers and/or liver biopsy. Liver Int.29(Suppl. 1), 19–22 (2009).
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1(5), 431–435 (1981).
   PubMed Web of Science ®Google Scholar
• No authors listed. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology20(1 Pt 1), 15–20 (1994).
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol.22(6), 696–699 (1995).
   PubMed Web of Science ®Google Scholar
• Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J. Viral Hepat.16(5), 300–314 (2009).
   PubMed Web of Science ®Google Scholar
• Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J. Hepatol.48(4), 606–613 (2008).
   PubMed Web of Science ®Google Scholar
• Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology39(4), 1147–1171 (2004).
   PubMed Web of Science ®Google Scholar
• Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol.42(5), 615–624 (2005).
   PubMed Web of Science ®Google Scholar
• Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol.48(5), 835–847 (2008).
   PubMed Web of Science ®Google Scholar
• Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepat.14(5), 360–369 (2007).
   PubMed Web of Science ®Google Scholar
• Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet357(9262), 1069–1075 (2001).
   PubMed Web of Science ®Google Scholar
• Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology36(4 Pt 1), 986–992 (2002).
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology38(2), 518–526 (2003).
   PubMed Web of Science ®Google Scholar
• Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J. Hepatol.41(6), 935–942 (2004).
   PubMed Web of Science ®Google Scholar
• Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem.51(10), 1867–1873 (2005).
   PubMed Web of Science ®Google Scholar
• Cales P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology42(6), 1373–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J. Hepatol.46(3), 528–529; author reply 529–530 (2007).
   PubMed Web of Science ®Google Scholar
• Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J. Hepatol.48(Suppl. 1), S68–S92 (2008).
   PubMed Web of Science ®Google Scholar
• de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J. Hepatol.43(1), 167–176 (2005).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology42(5), 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol.48(Suppl. 1), S20–S37 (2008).
   PubMed Web of Science ®Google Scholar
• Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J. Hepatol.42(2), 218–224 (2005).
   PubMed Web of Science ®Google Scholar
• Hassan MM, Hwang LY, Hatten CJ et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology36(5), 1206–1213 (2002).
   PubMed Web of Science ®Google Scholar
• Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut48(2), 251–259 (2001).
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology126(4), 1005–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol.35(3), 421–430 (2001).
   PubMed Web of Science ®Google Scholar
• Trinchet J, Beaugrand M. A randomized trial comparing 3-month vs 6-month screening for HCC by ultrasound in cirrhosis. Abstract book. International Liver Cancer association (ILCA) (2007).
   Google Scholar
• Adam R, McMaster P, O’Grady JG et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl.9(12), 1231–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Lucey MR, Brown KA, Everson GT et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl. Surg.3(6), 628–637 (1997).
   PubMedGoogle Scholar
• Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med.334(13), 815–820 (1996).
   PubMed Web of Science ®Google Scholar
• Roche B, Samuel D. Liver transplantation in viral hepatitis: prevention of recurrence. Best Pract. Res. Clin. Gastroenterol.22(6), 1153–1169 (2008).
   PubMed Web of Science ®Google Scholar
• Feray C, Caccamo L, Alexander GJ et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology117(3), 619–625 (1999).
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med.343(23), 1673–1680 (2000).
   PubMed Web of Science ®Google Scholar
• Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl.9(11), S90–S94 (2003).
   Web of Science ®Google Scholar